Compare Paycom Software Inc (PAYC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs TG Therapeutics Inc — how do they compare? Paycom Software Inc trades at $139 (market cap $6.72B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Paycom Software Inc pays a 1.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PAYC | TGTX | |
|---|---|---|
Market Cap | $6.72B | $8.26B |
Sector | Technology | Health |
52-Week High | $238.80 | $59.06 |
52-Week Low | $113.59 | $26.39 |
Enterprise Value | $7.33B | $8.50B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $144.22, down 2.51% today, with a bullish technical signal and strong fundamentals including 22.44% net margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company launched a new Asset Management tool. Cash flow from operations grew to $679M in 2025, though net cash flow declined from 2024's peak.
Outlook remains positive with analyst consensus near current price ($144.60 target) and 47% buy ratings. Risks include high P/B of 8.6 and reliance on HR software demand. The stock offers value with a reasonable P/E of 17.33 but faces execution risks in maintaining growth against competition.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
